Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma

Wen-Hui Chen1†, Lin-Quan Tang1,2†, Feng-Wei Wang1, Chang-Peng Li1, Xiao-Peng Tian1, Xiao-Xia Huang1, Shi-Juan Mai1, Yi-Ji Liao1, Hai-Xia Deng1, Qiu-Yan Chen1,2, Huai Liu1,2, Lu Zhang1,2, Shan-Shan Guo1,2, Li-Ting Liu1,2, Shu-Mei Yan1,3, Chao-Feng Li1,4, Jing-Ping Zhang1,5, Qing Liu1,6, Xue-Wen Liu1,7, Li-Zhi Liu1,7, Hai-Qiang Mai1,2*, Mu-Sheng Zeng1* and Dan Xie1*

Abstract

Background: Hemostatic alterations occur during the development of cancer. Plasma D-dimer is a hypercoagulability and fibrinolytic system marker that is increased in patients with various solid tumours. The aim of this study was to evaluate the hemostatic status of nasopharyngeal carcinoma (NPC) patients by assessing plasma D-dimer levels to investigate its value as a prognostic marker.

Methods: We retrospectively analysed 717 patients with nasopharyngeal carcinoma, and we applied Cox regression and log-rank tests to assess the association of D-dimer levels with disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS). D-dimer levels were measured using a quantitative D-dimer latex agglutination assay.

Results: Using the 3rd quartile values (0.8 μg/L) as the optimal cut-offs, we found that patients with high D-dimer levels have a shorter 3-year DFS, (79%, 95%CI (73.1–84.9)) vs. (69%, 95%CI (59.2–78.8)), DMFS (87%, 95%CI (83.1–90.9)) vs. (77%, 95%CI (69.2–84.8)), and overall survival (82%, 95%CI (76.1–87.9)) vs. (76%, 95%CI (66.2–85.8)). Multivariate analysis revealed that pre-treatment D-dimer levels and EBV DNA were significant independent factors for DFS, DMFS, and OS in NPC patients. Subgroup analyses indicated that the plasma D-dimer levels could effectively stratify patient prognosis for early cancer, advanced stage cancer, and patients with EBV DNA ≥4000 copies/ml.

Conclusions: High D-dimer levels were associated with poor disease-free survival, distant metastasis-free survival, overall survival, and increased risk of mortality in NPC patients. Prospective trials are required to assess the prognostic value of D-dimer levels.

Keywords: Nasopharyngeal carcinoma, D-dimer, Survival

Background

Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in southern China, southeastern Asia, and northern Africa. The lowest prevalence of NPC is found in white populations from Europe and the United States [1-3]. Radiotherapy regimens are currently the primary treatment strategy for NPC patients. Although the TNM staging system [4] is currently the most powerful prognostic factor for NPC, patients with the same stage and similar treatment regimens have variable clinical outcomes. The expression of several specific biological markers have been used to provide additional prognostic information for NPC patients, including epidermal growth factor receptor [5], serum lactate dehydrogenase (LDH) [6], C-reactive protein (CRP) [7], and plasma Epstein-Barr virus DNA (EBV DNA) [8]. Several studies have investigated pre-treatment EBV DNA,
which is used for disease monitoring and prognosis prediction in the clinic [8-10]. Several studies have suggested an association between a more aggressive cancer phenotype and hypercoagulability [11,12]. Interestingly, in the absence of venous thromboembolism (VTE), the systemic activation of blood coagulation and procoagulant changes in the hemostatic system are frequently been observed in cancer patients [13,14]. Patients with cancer and hypercoagulation have a higher risk of venous thrombosis and a poor prognosis [15]. It has been reported that many increased or decreased coagulation factors contribute to cancer growth, progression and metastasis [16]. The plasma D-dimer is a stable end product of fibrin degradation, and it is a useful biomarker for predicting venous thromboembolism (VTE) in cancer patients [17]. Increased D-dimer levels are related to tumour stage, tumour prognosis and lymph node involvement. Additionally, D-dimer levels are a negative prognostic indicator for several malignancies, including breast [18], colorectal [19], lung [20], and prostate cancer [21]. Elevated D-dimer levels may reflect multifactorial interactions between carcinoma growth and the hemostatic-fibrinolytic system in malignancy. However, the clinical significance of D-dimer in nasopharyngeal carcinoma has not been established.

The purpose of this study was to analyse the prognostic value of plasma D-dimer levels in patients with NPC and evaluate the correlation between pre-treatment plasma D-dimer levels and clinical-pathological parameters. The results of our study will help predict NPC progression in patients and provide information for further treatment.

**Methods**

**Patient selection**

The principal inclusion criteria were as follows: (1) biopsy-proven primary NPC, no radiotherapy, chemotherapy, or oncologic surgery history, and an ECOG of 0 to 2; (2) patient age ≥18 years; (3) adequate hematologic, renal, and hepatic function (white blood cell count of ≥4000/μL, platelet count of ≥100,000/μL, serum creatinine clearance ≥50 mL/min, total serum bilirubin concentration <1.5 mg/dL); and (4) available follow-up data. The following exclusion criteria were used for our study: (1) patients who had a history of venous thrombosis or anticoagulation therapy within 3 months before treatment; (2) patients with previous or coexisting cancer other than NPC; (3) pregnancy and lactation; or (4) stroke or neurosurgery within 6 months. Between January 2008 and December 2011, a total of 717 consecutive non-distant-metastatic NPC patients (average age of 47, ranging from 29 to 71 years old) were enrolled at Sun Yat-sen University Cancer Center (Guangzhou, China). During the same time period, 126 healthy volunteers (average age of 45, ranging from 19 to 75 years old) who submitted to D-dimer testing as part of a routine physical examination in our hospital were enrolled as the control group. This retrospective study was approved by the Clinical Research Ethics Committee of the Sun Yat-sen University Cancer Center, and all the participants provided written informed consent before treatment.

The routine staging patient work-up included the following clinical examinations of the head and neck region: magnetic resonance imaging scans from the suprasellar cistern to the collarbone, fibre optic nasopharyngoscopy, chest radiography, abdominal sonography, whole-body bone scan or whole body FDG PET/CT. All patients were restaged according to the seventh American Joint Committee on Cancer (AJCC) TNM staging manual. All clinical records and magnetic resonance images were independently reviewed by 2 radiologists (X.W.L and L.Z.L.) to minimize heterogeneity in restaging. Before treatment, the following baseline clinical data were collected from the medical records and information system at the study institute: sex, age, WBC counts, neutrophil counts, haemoglobin (HGB), platelet counts, LDH, CRP, hereditary NPC, smoking status, PS by Eastern Cooperative Oncology Group (ECOG), and the presence of concurrent diseases, such as cardiovascular disease, diabetes and chronic hepatitis.

**Treatment delivery**

One hundred and sixty-seven (23.3%) patients were treated with conventional two-dimensional (2D-CRT) or three-dimensional conformal radiotherapy (3D-CRT), and the remaining 550 (76.7%) patients were treated with intensity-modulated radiotherapy (IMRT). Details of the radiotherapy techniques used at the Sun Yat-sen University Cancer Center were reported in a previous study [22,23]. Six hundred and forty (91.3%) patients with stage II–IV disease received concurrent platinum-based chemotherapy. A stratified multi-therapeutic protocol was used to treat patients. Radiation therapy alone was used for stage I disease, and radiation with concurrent platinum-based chemotherapy was used to treat stage II disease [24]. Concurrent chemoradiotherapy, with or without neoadjuvant or adjuvant chemotherapy, was used for advanced-stage disease (stages III and IV). Neoadjuvant or adjuvant chemotherapy consisted of cisplatin with 5-fluorouracil or cisplatin with taxane administered every 3 weeks for 2 or 3 cycles [25]. The concurrent chemotherapy regimen consisted of cisplatin given on weeks 1, 4, and 7 of RT, or weekly cisplatin. All the patients at the study institution were treated according to the principle of treatment for NPC patients at Sun Yat-sen University Cancer Center, Guangzhou, China.
D-dimer evaluation
A 3 mL fasting blood sample was collected before treatment of NPC patients and on the day of physical examination for the healthy volunteers. The sample was processed within 3 hours of collection, and the plasma was stored at −70 to −80°C until analysis. D-dimer values were measured by a latex-enhanced immunoturbidimetric assay (Sekisui Medical Co., Ltd., Tokyo, Japan) using a Sysmex CA 7000 (Sysmex Corp., Kobe, Japan) analyser in the clinical hospital laboratory. The results were obtained using a standard curve prepared according to the manufacturer's instructions, and the inter-assay imprecision (coefficient of variation) was < 10%.

EBV DNA, VCA-IgA, and EA-IgA measurement
As described in previous studies [26-28], patient plasma EBV DNA concentrations were routinely measured by q-PCR before treatment. A cut-off level of 4000 copies/ml was chosen to define low and high EBV DNA levels because this threshold has previously been shown to be prognostic in NPC patients using the same measurement system [10,29]. EBV-specific VCA/IgA antibodies and EBV-specific EA/IgA antibodies were measured using a previously described immunoenzymatic assay [30].

Clinical outcomes assessment and patient follow-up
The primary endpoint of our study was disease-free survival (DFS). The secondary endpoints were distant metastasis-free survival (DMFS) and overall survival (OS). We calculated DFS from the date of the first NPC diagnosis to the date of the first relapse at any site, death from any cause or the date of the last follow-up visit. DMFS was calculated from the date of the first NPC diagnosis to the date of distant relapse or patient censoring at the date of the last follow-up. OS was calculated from the date of the first NPC diagnosis to the date of death from any cause or patient censoring at the date of the last follow-up. After treatment was completed, patients were evaluated at 3-month intervals for the first 3 years and every 6 months thereafter.

Statistical analysis
The characteristics of the patients were divided into quartiles and described by median values and the 25th-75th percentiles (due to non-normally distributed continuous variables). Mann–Whitney U-tests were used to compare continuous variables in different subgroups. The Spearman correlation test was used to examine the association between D-dimer levels and other variables. Survival curves were calculated by the Kaplan-Meier method, and univariate analyses were performed using the log-rank test. Variables that reached a p-value of ≤ 0.05 in the univariate analysis were entered into multivariate analyses. All statistical calculations were performed using SPSS 17.0 for Windows (Chicago, IL), and a P < 0.05 was considered statistically significant.

Results
Baseline characteristics and distribution of D-dimer level in the study population and subgroups
The pretreatment characteristics of the 717 NPC patients are listed in Table 1. The median follow-up was 31 months (IQR, 24–42). Forty-eight patients developed locoregional recurrences, and 85 patients developed distant metastases. Of these patients, 16 patients had both local and distant metastases. The plasma D-dimer level was higher in NPC patients than healthy volunteers (P < 0.001, Figure 1), with the values of 0.50 (25th-75th percentile: 0.3-0.8) and 0.4 µg/mL (25th-75th percentile: 0.3-0.5), respectively. The median D-dimer level was higher in patients with distant metastasis compared to patients without distant metastasis (P = 0.002, Figure 1), with values of 0.60 (25th-75th percentile: 0.4-1.0) and 0.50 (25th-75th percentile: 0.3-0.7), respectively. The D-dimer level was higher in patients with plasma EBVDNA ≥ 4000 copies than in patients with EBVDNA < 4000 copies (P = 0.002, Figure 1), with values of 0.50 (25th-75th percentile: 0.3-0.9) and 0.50 (25th-75th percentile: 0.3-0.7), respectively. Patients who died during the observation period had significantly higher D-dimer levels at baseline than patients who were alive at the end of the study or the last follow-up: 0.6 (25th-75th percentile: 0.4-0.925) and 0.5 (25th-75th percentile: 0.3-0.7), respectively (P = 0.002, Figure 1). A Spearman correlation analysis further demonstrated that plasma D-dimer levels correlated with age, serum CRP level, LDH level, EBV DNA level, tumour TNM stage, and distant metastasis (Additional file 1: Table S1).

D-dimer levels and probability of survival
For the Kaplan–Meier analysis, patients were categorised into the following four groups according to their D-dimer levels: the 1st group (D-dimer levels ranging from minimum to 1st quartile of D-dimer levels in the total cohort population: 0.0-0.3 µg/mL), 2nd group (D-dimer levels from 1st quartile to 2nd quartile: 0.3-0.5 µg/mL), 3rd group (D-dimer levels from 2nd quartile to 3rd quartile: 0.5-0.8 µg/mL) and 4th group (D-dimer levels from 3rd quartile to maximum: 0.8-37.2 µg/mL). Additional file 1: Figure S1 shows the Kaplan-Meier estimates for DFS, DMFS and OS according to D-dimer levels. Elevated D-dimer levels were significantly associated with shorter DFS, DMFS and OS (log-rank trend test: P < 0.001).

Using the 1st group as a reference, the unadjusted hazard ratio (HR) for DFS, DMFS, and OS of the top quartiles were 2.26 (95% CI, 1.38-3.70), 2.99 (95% CI, 1.63-5.48), and 3.06 (95% CI, 1.70-5.51), respectively. A similar trend of adjusted HR was observed for DFS,
Table 1 Patient demographics and clinical characteristics

| Characteristic                  | Median (25th-75th percentile) or No. (%) | NPC patients (n = 717) | Control (n = 126) |
|--------------------------------|----------------------------------------|------------------------|-------------------|
| Age at study entry             |                                        | 47 (39–47)             | 45 (39–53)        |
| Sex                            |                                        |                        |                   |
| Male                           |                                        | 533 (74.3)             | 102 (81)          |
| Female                         |                                        | 184 (25.7)             | 24 (19.0)         |
| D-dimer                        |                                        | 0.50 ug/mL (0.3-0.8)   | 0.40 ug/mL (0.3-0.5) |
| Histology, WHO type            |                                        |                        |                   |
| III                            |                                        | 690 (96.2)             |                   |
| II                             |                                        | 27 (3.8)               |                   |
| ECOG                           |                                        |                        |                   |
| 0-1                            |                                        | 712 (99.3)             |                   |
| 2                              |                                        | 5 (0.7)                |                   |
| Clinical stage                 |                                        |                        |                   |
| I                              |                                        | 16 (2.2)               |                   |
| II                             |                                        | 80 (11.2)              |                   |
| III                            |                                        | 416 (58.0)             |                   |
| IV                             |                                        | 205 (28.6)             |                   |
| Tumour stage                   |                                        |                        |                   |
| T1                             |                                        | 54 (7.5)               |                   |
| T2                             |                                        | 128 (17.9)             |                   |
| T3                             |                                        | 367 (51.2)             |                   |
| T4                             |                                        | 168 (23.4)             |                   |
| Node stage                     |                                        |                        |                   |
| N0                             |                                        | 112 (15.6)             |                   |
| N1                             |                                        | 273 (38.1)             |                   |
| N2                             |                                        | 277 (38.6)             |                   |
| N3                             |                                        | 55 (7.7)               |                   |
| Treatment                      |                                        |                        |                   |
| Radiotherapy                   |                                        | 75 (10.5)              |                   |
| Chemotherapy and radiotherapy  |                                        | 642 (89.5)             |                   |
| Radiotherapy technique         |                                        |                        |                   |
| 2DRT/3DCRT                     |                                        | 167 (23.3)             |                   |
| IMRT                           |                                        | 550 (76.7)             |                   |
| EBVDNA                         |                                        |                        |                   |
| Low DNA                        |                                        | 411 (57.3)             |                   |
| High DNA                       |                                        | 306 (42.7)             |                   |
| VCA-IgA                        |                                        |                        |                   |
| <1:80                          |                                        | 223 (31.1)             |                   |
| ≥1:80                          |                                        | 494 (68.9)             |                   |
| EA-IgA                         |                                        |                        |                   |
| <1:10                          |                                        | 315 (43.9)             |                   |
| (Continued)                    |                                        |                        |                   |
| LDH, U/L                       |                                        |                        |                   |
| < 167                          |                                        | 353 (49.2)             |                   |
| ≥ 167                          |                                        | 364 (50.8)             |                   |
| CRP, mg/L                      |                                        |                        |                   |
| < 1.61                         |                                        | 359 (50.1)             |                   |
| ≥ 1.61                         |                                        | 358 (49.9)             |                   |
| WBC, 109/L                     |                                        |                        |                   |
| < 6.7                          |                                        | 362 (50.5)             |                   |
| ≥ 6.7                          |                                        | 355 (49.5)             |                   |
| Neutrophil, 109/L              |                                        |                        |                   |
| < 4.0                          |                                        | 359 (50.2)             |                   |
| ≥ 4.0                          |                                        | 358 (49.8)             |                   |
| HGB, g/L                       |                                        |                        |                   |
| < 143.8                        |                                        | 359 (50.1)             |                   |
| ≥ 143.8                        |                                        | 358 (49.9)             |                   |
| PLT, 109/L                     |                                        |                        |                   |
| < 227                          |                                        | 359 (50.1)             |                   |
| ≥ 227                          |                                        | 358 (49.9)             |                   |
| Smoking                        |                                        |                        |                   |
| yes                            |                                        | 259 (63.9)             |                   |
| no                             |                                        | 458 (36.1)             |                   |
| Chronic HBV Infection          |                                        |                        |                   |
| yes                            |                                        | 57 (7.9)               |                   |
| no                             |                                        | 660 (92.1)             |                   |
| Cardiovascular disease         |                                        |                        |                   |
| yes                            |                                        | 61 (8.5)               |                   |
| no                             |                                        | 656 (91.5)             |                   |
| Diabetes mellitus              |                                        |                        |                   |
| yes                            |                                        | 22 (3.1)               |                   |
| no                             |                                        | 695 (96.9)             |                   |
| Family history of NPC          |                                        |                        |                   |
| yes                            |                                        | 61 (8.5)               |                   |
| no                             |                                        | 656 (91.5)             |                   |
| Median follow-up (months)      |                                        |                        |                   |
| Outcome features               |                                        |                        |                   |
| Progression                    |                                        |                        |                   |
| yes                            |                                        | 118 (16.5)             |                   |
| no                             |                                        | 599 (83.5)             |                   |
| Distant metastasis             |                                        |                        |                   |
| yes                            |                                        | 85 (11.9)              |                   |
| no                             |                                        | 632 (88.1)             |                   |
DMFS and OS. HRs and 95% CIs comparing quartiles of D-dimer for disease-free, distant metastasis and overall survival are detailed in Additional file 1: Table S2. The patients were divided into two groups based on whether the D-dimer level was above or below the top quartiles (0.8 μg/L). Patients with high D-dimer levels had a shorter 3-year DFS, (79%, 95%CI (73.1–84.9)) vs. (69%, 95%CI (59.2–78.8)), DMFS (87%, 95%CI (83.1–90.9)) vs. (77%, 95%CI (69.2–84.8)), and overall survival (82%, 95%CI (76.1–87.9)) vs. (76%, 95%CI (66.2–85.8)) (Figure 2).

Univariate and multivariate analyses of prognostic factors
As shown in Table 2, using 0.8 ug/L as a cut-off value, the hazard ratios (HRs) and 95% CIs estimated from Cox regression models indicated that the D-dimer level was strongly associated with DFS, DMFS, and OS (HR, 1.88; 95% CI, 1.28 to 2.77), (HR, 2.16; 95%CI, 1.38 to 3.36) and (HR, 1.98; 95%CI, 1.29 to 3.04), respectively. In addition to elevated D-dimer levels, the UICC TNM classification, high EBV DNA and elevated CRP levels (1.61 mg/L) were significantly associated with DFS, DMFS, and OS.

Multivariate analysis indicated that elevated D-dimer levels were a highly significant predictor for DFS, DMFS, and OS, independent of EBV DNA level, LDH level, CRP levels, UICC TNM staging, smoking status, and treatment type (Table 3).

Prognostic significance of D-dimer within the UICC TNM classification, and patients with high or low EBV DNA level
Given the independent prognostic significance of elevated D-dimer levels in NPC patients, we evaluated the discrimination power of elevated D-dimer levels in early-stage and advanced-stage patients. Compared to patients with low D-dimer levels, patients with early-stage and advanced-stage disease with elevated D-dimer levels had shorter DFS, DMFS, and OS (Figure 3).

Consistent with previous reports [10,29], we chose 4000 copies/ml to define the low and high pre-treatment levels.

### Table 1 Patient demographics and clinical characteristics (Continued)

| Local/regional recurrence | yes | no |
|---------------------------|-----|----|
|                           | 48  | 669|
| Deaths                    | yes | no |
|                           | 94  | 623|

Abbreviations: ECOG Eastern Cooperative Oncology Group, 2DRT two-dimensional radiotherapy, 3D CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, Low DNA denotes a high EBV DNA level of <4000 copies/ml, High DNA denotes a high EBV DNA level of ≥4000 copies/ml, VCA viral capsid antigen, IgA immunoglobulin A, EA early antigen, LDH Serum Lactate Dehydrogenase Levels, CRP high-sensitivity C-reactive protein, WBC White blood cell, HGB haemoglobin, PLT platelet, NPC nasopharyngeal carcinoma.

---

**Figure 1** Plasma D-dimer levels are expressed as the median and 5%-95% percentile in patients with nasopharyngeal carcinoma according to different variables. (A) Healthy volunteers versus nasopharyngeal carcinoma patients; (B) Nasopharyngeal carcinoma with distant metastasis after treatment versus non-distant metastasis (P = 0.002); (C) Non-survivors versus survivors (P = 0.002); (D) High DNA (≥4000 copies/ml) versus low DNA (<4000 copies/ml) (P = 0.002).
Figure 2 Kaplan-Meier curves of disease-free survival (A), distant metastasis-free survival (B), and overall survival (C) of the entire NPC population according to pre-treatment D-dimer levels (n = 717).

Table 2 Univariate Cox proportional hazards regression analysis

| Characteristic                     | DFS (n = 717) | DMFS (n = 717) | OS (n = 717) |
|-----------------------------------|---------------|----------------|--------------|
|                                   | HR  | 95% CI | P   | HR  | 95% CI | P   | HR  | 95% CI | P   |
| Age, (≥47 vs. < 47 years)         | 0.73 | 0.51 to 1.06 | 0.100 | 0.87 | 0.56 to 1.33 | 0.517 | 0.85 | 0.56 to 1.29 | 0.444 |
| Male vs. Female                    | 1.08 | 0.71 to 1.65 | 0.726 | 1.18 | 0.86 to 1.65 | 0.162 | 0.92 | 0.64 to 1.65 | 0.922 |
| Histology, WHO type (III vs. II)  | 0.95 | 0.42 to 2.53 | 0.949 | 0.69 | 0.28 to 1.70 | 0.689 | 1.78 | 0.56 to 5.62 | 0.328 |
| ECOG (2 vs. 0–1)                   | 0.10 | 0.05 to 0.215 | 0.927 | 1.05 | 0.36 to 3.63 | 0.596 | 1.25 | 0.14 to 8.99 | 0.824 |
| Clinical stage (III-IV) vs. (I-II)  | 3.05 | 1.34 to 6.94 | 0.008 | 4.43 | 1.40 to 14.01 | 0.011 | 2.56 | 1.04 to 6.31 | 0.041 |
| Tumour stage (T3-4 vs. T1-2)      | 1.47 | 0.93 to 2.31 | 0.100 | 1.65 | 0.94 to 2.88 | 0.08 | 1.32 | 0.80 to 2.18 | 0.286 |
| Node stage (N2-3 vs. N0-1)        | 1.72 | 1.19 to 2.48 | 0.004 | 2.19 | 1.40 to 3.42 | 0.001 | 1.75 | 1.16 to 2.66 | 0.008 |
| Chemoradiotherapy (yes v no)      | 1.94 | 0.90 to 4.17 | 0.089 | 1.58 | 0.69 to 3.63 | 0.279 | 1.59 | 0.70 to 3.64 | 0.27 |
| IMRT vs. 2DRT/3D CRT               | 0.55 | 0.38 to 0.80 | 0.002 | 0.66 | 0.42 to 1.04 | 0.071 | 0.88 | 0.57 to 1.34 | 0.537 |
| High DNA Vs. Low DNA              | 2.97 | 2.02 to 4.36 | < 0.001 | 3.69 | 2.30 to 5.91 | < 0.001 | 3.50 | 2.23 to 5.50 | < 0.001 |
| CRP, mg/L (≥1.61 vs. < 1.61)      | 1.43 | 0.99 to 2.06 | 0.055 | 1.83 | 1.18 to 2.84 | 0.007 | 1.87 | 1.23 to 2.85 | 0.003 |
| VCA-IgA (≥180 vs. < 180)          | 1.39 | 0.91 to 2.13 | 0.127 | 1.32 | 0.81 to 2.16 | 0.267 | 0.95 | 0.64 to 1.61 | 0.952 |
| EA-IgA (≥10 vs. < 10)             | 1.23 | 0.85 to 1.77 | 0.282 | 1.17 | 0.76 to 1.81 | 0.477 | 0.99 | 0.66 to 1.50 | 0.977 |
| LDH, U/L (≥167 vs. < 167)         | 1.41 | 0.98 to 2.04 | 0.064 | 1.67 | 1.07 to 2.59 | 0.002 | 1.38 | 0.92 to 2.08 | 0.125 |
| D-dimer, ug/L (≥0.8 vs. < 0.8)    | 1.88 | 1.28 to 2.77 | 0.001 | 2.16 | 1.38 to 3.36 | 0.001 | 1.98 | 1.29 to 3.04 | 0.002 |
| WBC, 10^9/L (≥6.7 vs. < 6.7)      | 1.06 | 0.90 to 1.25 | 0.753 | 1.17 | 0.76 to 1.9 | 0.481 | 1.08 | 0.72 to 1.62 | 0.709 |
| Neutrophil, 10^9/L (≥2.41 vs. < 2.41) | 1.09 | 0.76 to 1.56 | 0.658 | 1.03 | 0.67 to 1.57 | 0.9 | 1.24 | 0.82 to 1.87 | 0.308 |
| HGB, g/l (≥143.8 vs. < 143.8)     | 0.87 | 0.61 to 1.25 | 0.463 | 0.82 | 0.53 to 1.25 | 0.35 | 0.77 | 0.51 to 1.16 | 0.207 |
| PLT, 10^9/L (≥227 vs. < 227)      | 1.13 | 0.79 to 1.62 | 0.511 | 1.08 | 0.71 to 1.66 | 0.712 | 1.23 | 0.82 to 1.84 | 0.33 |
| Smoking (yes v no)                | 1.27 | 0.88 to 1.84 | 0.196 | 1.59 | 1.04 to 2.44 | 0.033 | 1.22 | 0.81 to 1.84 | 0.346 |
| Chronic HBV Infection (yes v no)  | 1.00 | 0.84 to 1.18 | 0.953 | 1.02 | 0.84 to 1.23 | 0.881 | 0.97 | 0.80 to 1.18 | 0.969 |
| Cardiovascular disease (yes v no) | 1.16 | 0.61 to 2.22 | 0.653 | 1.28 | 0.62 to 2.67 | 0.25 | 1.64 | 0.79 to 3.41 | 0.014 |
| Diabetes mellitus (yes v no)      | 0.94 | 0.85 to 1.05 | 0.286 | 0.97 | 0.87 to 1.08 | 0.592 | 0.94 | 0.84 to 1.05 | 0.248 |
| Family history of NPC (yes v no)  | 1.14 | 0.61 to 2.11 | 0.686 | 1.13 | 0.55 to 2.35 | 0.735 | 1.14 | 0.92 to 1.41 | 0.241 |

Abbreviations: ECOG Eastern Cooperative Oncology Group, 2DRT two-dimensional radiotherapy, 3D CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA level of <4000 copies/ml, High DNA denotes a high EBV DNA level of ≥4000 copies/ml, VCA viral capsid antigen, IgA immunoglobulin A, EA early antigen, LDH Serum Lactate Dehydrogenase Levels, CRP high-sensitivity C-reactive protein, WBC White blood cell, HGB haemoglobin, PLT platelet, NPC nasopharyngeal carcinoma, DFS disease-free survival, DMFS metastasis-free survival, OS overall survival.
EBV DNA level. In subgroup analysis, patients in the high EBV DNA subgroup with elevated D-dimer levels had a worse DFS, DMFS, and OS compared with the patients with low D-dimer levels. For patients with low EBV DNA levels, there was no difference in DFS, DMFS, and OS between the patients with low or high D-dimer levels (Figure 4).

Discussion
To our knowledge, this is the first large-scale cohort study examining the association between coagulation and survival in nasopharyngeal carcinoma patients. The activation of coagulation in cancer patients is widely implicated in both tumour progression and the development of thrombosis [31]. High levels of plasma D-dimer

---

**Table 3 Multivariate Cox proportional hazards regression analysis**

| Characteristic                        | DFS (n = 717) |          |          | DMFS (n = 717) |          |          | OS (n = 717) |          |          |
|---------------------------------------|--------------|----------|----------|--------------|----------|----------|--------------|----------|----------|
|                                      | HR           | 95% CI   | P        | HR           | 95% CI   | P        | HR           | 95% CI   | P        |
| Tumour stage (T3-4 vs. T1-2)         | 1.23         | 0.76 to 1.99 | 0.395    | 1.36         | 0.76 to 2.45 | 0.305    | 1.04         | 0.61 to 1.79 | 0.88    |
| Node stage (N2-3 vs. N0-1)           | 1.14         | 0.76 to 1.71 | 0.516    | 1.43         | 0.88 to 2.33 | 0.148    | 1.08         | 0.68 to 1.72 | 0.756   |
| Chemoradiotherapy (yes vs. no)       | 1.23         | 0.55 to 2.74 | 0.621    | 0.84         | 0.40 to 2.02 | 0.7      | 0.89         | 0.36 to 2.18 | 0.793   |
| IMRT vs. 2DRT/3DCRT                  | 0.62         | 0.42 to 0.90 | 0.013    | 0.76         | 0.48 to 1.21 | 0.246    | 0.99         | 0.64 to 1.52 | 0.954   |
| High DNA vs. Low DNA                 | 2.41         | 1.59 to 3.64 | < 0.001  | 2.77         | 1.66 to 4.62 | < 0.001  | 3.06         | 1.87 to 5.02 | < 0.001 |
| CRP, mg/L (≥1.61 vs. < 1.61)         | 1.14         | 0.78 to 1.68 | 0.495    | 1.35         | 0.85 to 2.14 | 0.21     | 1.48         | 0.95 to 2.31 | 0.082   |
| LDH, U/L (≥167 vs. < 167)            | 1.22         | 0.84 to 1.77 | 0.290    | 1.35         | 0.86 to 2.11 | 0.189    | 1.23         | 0.81 to 1.86 | 0.34    |
| D-dimer, ug/L (≥0.8 vs. < 0.8)       | 1.60         | 1.08 to 2.37 | 0.020    | 1.79         | 1.13 to 2.82 | 0.013    | 1.58         | 1.02 to 2.45 | 0.043   |
| Smoking (yes vs. no)                 | 1.26         | 0.87 to 1.82 | 0.216    | 1.58         | 1.03 to 2.43 | 0.036    | 1.35         | 0.89 to 2.06 | 0.159   |

Abbreviations: ECOG Eastern Cooperative Oncology Group, 2DRT two-dimensional radiotherapy, 3DCRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA level of <4000 copies/ml, High DNA denotes a high EBV DNA level of ≥4000 copies/ml, LDH Serum Lactate Dehydrogenase Levels, CRP high-sensitivity C-reactive protein, DFS disease-free survival, DMFS metastasis-free survival, OS overall survival.

Figure 3 Kaplan-Meier curves of disease-free survival (A), distant metastasis-free survival (B), and overall survival (C) of NPC patients with early stage (I + II, n = 96), and disease-free survival (D), distant metastasis-free survival (E), and overall survival (F) of NPC patients with advanced stage (III + IV, n = 621), according to pre-treatment D-dimer levels.
have been associated with poor prognosis in several malignant diseases, including lung pancreas, prostate, gastric, colorectal, and breast cancer [19,20,32,33]. Recently, Liu et al. [32] demonstrated that elevated plasma D-dimer was correlated with depth of invasion, lymph node metastasis, peritoneal dissemination, distant metastasis, tumour size, TNM stage, and worse overall survival in gastric cancer. Interestingly, according to our findings, the D-dimer plasma level is a marker of endogenous fibrinolysis that can be used to evaluate hypercoagulability, and it has both clinical and prognostic significance in nasopharyngeal carcinoma patients. With a median follow-up of 3 years, the HR of DFS, DMFS, and OS in cancer patients with the highest D-dimer levels in the total study population (D-dimer levels ranging from 3rd quartile to the maximum level) was two-fold higher than patients with D-dimer levels ranging from the minimum to the 1st quartile. Using the 3rd quartile (0.8 μg/mL) as the final cut-off, multivariate analysis revealed that pre-treatment D-dimer levels were a significant, independent prognostic factor for predicting recurrence, distant metastasis, and death. This effect was independent of EBV DNA level, LDH level, CRP levels, UICC TNM staging, smoking status, and treatment type (Table 3).

Plasma EBV DNA has been demonstrated to be correlated with tumour burden [34], TNM stage [35], response to chemoradiotherapy [36-38], and survival in NPC patients [8,10,29]. Plasma EBV DNA is now a useful biomaker for the clinical management of NPC patients, and it is considered the most attractive potential biomarker [37]. However, for NPC patients with EBV DNA ≥4000 copies/ml, patients with D-dimer ≥0.8 μg/L still have a shorter DFS, DMFS, and OS compared to patients with D-dimer < 0.8 μg/L. However, this result does not apply to patients with EBV DNA < 4000 copies/ml. Although the magnitude of the predictive value of EBV DNA was superior to that of D-dimer, it is not sufficient to use plasma EBV DNA alone for prognostic stratification due to the heterogeneity of NPC patients. Notably, patients in the high EBV DNA subgroup with high plasma D-dimer levels had a worse disease-free survival, distant metastasis-free survival, and overall survival. These results indicate that EBV DNA alone is insufficient to complement the TNM classification, and plasma D-dimer levels represent a complementary marker to EBV DNA levess for the prediction of NPC patient prognosis.

Although the mechanism underlying D-dimer-mediated NPC progression of remains unknown, it is likely due to different D-dimer signalling pathways or biological
behaviours. The association between the D-dimer levels and NPC progression may be explained by abnormalities in haemostasis and fibrinolysis during tumour pathogenesis. The activation of coagulation is the result of increased tissue factor expression, which leads to fibrin deposition. Tumour cells also express tissue factors, and they might contribute to a variety of pathological processes, such as VTE, metastatic spread, tumour growth, and tumour angiogenesis [39].

Interestingly, elevated D-dimer levels still predicted a poorer DFS, DMFS, and OS for early and advanced stage NPC patients in both high and low EBV DNA subgroups, independent of TNM staging (Figure 3). Recent advancements in NPC patient classification and NPC molecular alterations have been made, including microRNA signatures [40] and the NPC-SVM classifier [41]. However, these developments require expensive and complicated procedures, and rapid clinical implementation was difficult to achieve in a short time. Plasma D-dimer levels are established, routinely measured blood-based parameters that are reproducibly detected without additional laborious efforts before use in clinical applications. These findings have great clinical relevance because D-dimer subgroups with different prognoses in defined TNM stages indicate the need for individual treatment for NPC patients in the future. The association between pre-treatment D-dimer levels and TNM stage may be helpful for screening NPC patients. If a patient displays an abnormally high D-dimer level before treatment, they may require more intensive systemic approaches to improve the treatment outcome.

However, there are still some limitations to the present study, such as the single D-dimer measurements recorded from a single centre. Another limitation of this study is that we neglected to collect data for venous thromboembolism (VTE) events. High D-dimer levels have previously been reported to predict VTE in cancer patients [42,43], and both D-dimer and VTE are negative prognostic factors for cancer patients [33]. The third limitation was the short follow-up time, and additional patient data will be reported after the the 5 year follow-up.

Conclusions
In summary, we demonstrated that pre-treatment D-dimer levels can reflect hypercoagulability in NPC patients. Our results suggest that D-dimer is a promising prognostic biomarker associated with disease-free, distant metastasis-free and overall survival. D-dimmers represent a widely available potential biomarker, and the assays to detect D-dimer levels have been sufficiently validated. D-dimers should be considered for routine testing in NPC patients. A prospective study is needed to explore this area, and our results should be validated using other datasets.

Additional file

**Additional file 1: Figure S1.** Cumulative probability of disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival in the total study population (n=717). (1) Patients in the 1st group, with D-dimer levels ranging from minimum to 1st quartile (0.00 to 0.3 μg/mL) levels in the total study population, are compared to (2) those with D-dimer levels in the 2nd group, with levels between the 1st and 2nd quartiles (0.30 to 0.50μg/mL); (3) and those in the 3rd group, with levels between the 2nd and 3rd quartiles (0.50 to 0.80μg/mL); and (4) the 4th group, with D-dimer levels ranging from the 3rd quartile to maximum (0.80μg 3.72μg/mL) of D-dimer levels in the study population. The total numbers of patients with D-dimer levels in the 1st, 2nd, 3rd and 4th groups at study institute were 212, 202, 148 and 155, respectively. Table S1. D-dimer Relationships. **Table S2.** Prognostic value of D-dimer for DFS, DMFS, and OS by Quartiles.

Competing interests
We declare that the authors have no competing interest.

Authors’ contributions
W-HC and L-QT participated in the experimental work, literature research, study design, data collection, data analysis, interpretation of findings and the drafting of the manuscript. F-WW, C-PL, X-PT, X-XH, S-J M, Y-JL, Z-H, H-W, Q-YC. HL, LZ, S-SG, L-TL, J-PZ and S-MY collected blood samples, patient materials and patient follow-up information. X-WL, L-ZL reviewed MR images. C-FL and QL performed statistical analyses. H-QM, M-SZ and DX conceived of and coordinated the study, and critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We are grateful to the patients who participated in this study. This study was supported by grants from the Nature Science Foundation of China (No. 81225018, 81172340, 81172939, 81201629 and 81072226), the 863 Project (No: 2012AA02A501), the National Key Basic Research Program of China (No. 2013CB910304), the Sci-Tech Project Foundation of Guangdong Province (No. 2011B080701034, and 2011B031800161), and the Sci-Tech Project Foundation of Guangzhou City (No. 2011J4300100).

Author details
1. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Centre for Cancer Medicine, Guangzhou 510060, P. R. China. 2. Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China. 3. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China. 4. Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China. 5. Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China. 6. Department of Laboratory Service, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China. 7. Department of Medical Imaging, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China. 8. Imaging Diagnostic and Interventional Centre, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.

Received: 6 May 2014 Accepted: 30 July 2014
Published: 18 August 2014

References
1. Wee JT, Ha TC, Loong SL, Qian CN: Is nasopharyngeal cancer really a “Cantonesene cancer”? Chin J Cancer 2010, 29(5):517–526.
2. Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15(1):1765–1777.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69–90.
4. Tatsumi-Tamori A, Yoshizaki T, Miwa T, Furukawa M: Clinical evaluation of staging system for nasopharyngeal carcinoma: comparison of fourth and fifth editions of UICC TNM classification. Ann Otol Rhinol Laryngol 2000, 109(12 Pt 1):1125–1129.
5. Chua DT, Nicholls JM, Sham JS, Au GK: Prognostic value of epidermal growth factor receptor expression in patients with advanced stage...
Lippi G, Franchini M, Biasiutti C, Dellagiacoma G, Salvagno GL, Guidi GC.

Beer JH, Haeberli A, Vogt A, Furrer T, Fey MF.

Lin JC, Wang WY, Chen KY, Wei YL, Liang WM, Yan JS, Jiang RS.

Chen QY, Wen YF, Guo Y, Liu H, Huang PY, Lin CW, Lu TX, Cui NJ.

Xia WX, Zhang HB, SN JL, Lu X, Wang L, Ye YF, Cao KJ, Qian CN, Guo X, Xiang YQ.

Lyman GH, Khorana AA.

Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M.

Murray JC.

Xia WX, Zhang HB, Shi JL, Lu X, Wang L, Ye YF, Cao KJ, Qian CN, Guo X, Zeng YX.

Lyman GH, Khorana AA.

Chen et al. BMC Cancer 2014, 14:583

Chen QY, Wen YF, Guo Y, Liu H, Huang PY, Lin CW, Lu TX, Cui NJ.

Xia WX, Zhang HB, SN JL, Lu X, Wang L, Ye YF, Cao KJ, Qian CN, Guo X, Xiang YQ.

Lin JC, Wang WY, Chen KY, Wei YL, Liang WM, Yan JS, Jiang RS.

Chen QY, Wen YF, Guo Y, Liu H, Huang PY, Lin CW, Lu TX, Cui NJ, Xiang YQ, Guo Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J.

Chen J, Wang HY, Deng PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH.

Lo YM, Chan HY, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Embregt I, Zeng YX.

Lin Y, Huang Q, Liu W, Liu Q, Li W, Zhang E, Chen F, Liu Z, Guo X, Mo H, Chen J, Rao D, Ye W, Cao S, Hong M.

Nakashima J, Tachibana M, Ueno M, Baba S, Tazaki H.

Blackwell K, Carvalho MG.

Murray JC.

Lin J, Wang HY, Deng PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH.

Lo YM, Chan HY, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Embregt I, Zeng YX.

Lin J, Wang HY, Deng PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH.

Lo YM, Chan HY, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Embregt I, Zeng YX.

Lin J, Wang HY, Deng PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH.

Lo YM, Chan HY, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Embregt I, Zeng YX.

Lin J, Wang HY, Deng PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH.

Lo YM, Chan HY, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Embregt I, Zeng YX.

Lin J, Wang HY, Deng PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH.

Lo YM, Chan HY, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Embregt I, Zeng YX.

Lin J, Wang HY, Deng PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH.
patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009, 27(25):4124–4129.

43. Arpaia G, Carpenedo M, Verga M, Mastrogiacomo O, Fagnani D, Lanfredini M, Milani M, Cimminiello C: D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis 2009, 20(3):170–175.

doi:10.1186/1471-2407-14-583
Cite this article as: Chen et al.: Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma. BMC Cancer 2014 14:583.